Concepedia

Katherine Dawson

KD

20

Publications

4.4K

Citations

20

H-Index

2004

Active since

Affiliations

Biogen (United States)(Current)

St. Josef-Hospital

Ruhr University Bochum

Medical University of Lodz

Cleveland Clinic

Katherine Dawson is an author at Biogen (United States) specializing in medicine, neurology, and clinical trials.

Top concepts

Publications per year

2004–2023

20

Publications

20

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox, David H. Miller, J. Theodore Phillips et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Ludwig Kappos, Ralf Gold, David H. Miller et al. · The Lancet · 2008 · 477 citations · Full text

, , +6

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies

Sreeja Gopal, Alvydas Mikulskis, Ralf Gold et al. · Multiple Sclerosis Journal · 2017 · 100 citations

Rows per page

1–5 of 20